China SXT Pharmaceuticals (NASDAQ:SXTC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of China SXT Pharmaceuticals (NASDAQ:SXTC – Free Report) to a sell rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings upgraded shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Get China SXT Pharmaceuticals alerts:

Check Out Our Latest Research Report on SXTC

China SXT Pharmaceuticals Price Performance

NASDAQ:SXTC opened at $3.80 on Friday. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average of $106.34 and a 200 day moving average of $139.77. China SXT Pharmaceuticals has a 52 week low of $3.10 and a 52 week high of $83,758.80.

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) last announced its quarterly earnings results on Wednesday, July 1st. The company reported ($5.60) earnings per share (EPS) for the quarter. The business had revenue of $0.26 million for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SXTC. XTX Topco Ltd purchased a new stake in shares of China SXT Pharmaceuticals in the 4th quarter worth about $36,000. Virtu Financial LLC boosted its stake in shares of China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after purchasing an additional 15,013 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of China SXT Pharmaceuticals during the third quarter valued at about $78,000. 5.02% of the stock is owned by hedge funds and other institutional investors.

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.

Read More

• Five stocks we like better than China SXT Pharmaceuticals
• Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
• Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
• Snowflake Could Be Headed for New Highs Despite Insider Selling
• MongoDB Is Surging—And the Next Catalyst Is Almost Here

Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.